The Influence Of Rosiglitazone On The Expression Of HIF1α And IGF1in Myeloma Cells And The Study Of Its Possible Mechanism

Part I：The influence of rosiglitazone on the proliferation and expression ofHIF1α and IGF1of myeloma cells and primary myeloma cellsObjective：To observe the effect of rosiglitazone(RGZ) on myeloma cell proliferationand expression of HIF1α and IGF1mRNA.Methods：The expression of HIF1α and IGF1mRNA was detected in five newlydiagnosed MM patients and five iron deficiency anemia (control group) by RT-PCR.RPMI8226and primary myeloma cells from patients were treated with differentconcentrations of RGZ, MTT was used to detect the proliferation, the expression of HIF1αand IGF1mRNAwas analyzed after48h by RT-PCR.Results：We demonstrate a high expression of HIF1α and IGF1in RPMI8226and inprimary myeloma cells, the exposure to RGZ induced proliferation inhibition inRPMI8226in a dose-dependent manner and a significant decrease was observed in themRNAexpression of HIF1α and IGF1in RPMI8226and in primary myeloma cells.Conclusion：Our results suggest that rosiglitazone could inhibit RPMI8226cellsgrowth and the expression of HIF1α and IGF1mRNA. Part II：The influence of rosiglitazone on the expression of AKT and ERK inmyeloma cellsObjective：To observe the effect of rosiglitazone(RGZ) on the expression of AKTand ERK in the myeloma cells and to explore the possible mechanism. Methods： RPMI8226were treated with different concentrations of RGZ, theexpression of phosphorylated AKT,ERK and total proteins were detected by Westernblotting.Results：RGZ can inhibit pAKT and pERK in RPMI8226cells in a dose-dependentmanner with10,20and40μmol/L. However,the expression of total AKT and ERK proteinshowed no obvious difference.Conclusion：Our results suggest that rosiglitazone may inhibit the expression ofHIF1α and IGF1possibly by interfering with the PI3K/AKT and ERK signaling pathways.